- Home
- MBIO vs AIDX Comparison
MBIO vs AIDX Comparison
Compare MBIO & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBIO | AIDX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.9M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MBIO | AIDX |
|---|---|---|
| Price | $0.39 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.8K | ★ 71.5K |
| Earning Date | 11-06-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.99 | 34.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,045,133.00 |
| Revenue This Year | N/A | $44.20 |
| Revenue Next Year | $405.45 | $95.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.37 | $0.30 |
| 52 Week High | $1.69 | $18.96 |
Technical Indicators
Market Signals| Indicator | MBIO | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 30.11 | 24.20 |
| Support Level | N/A | N/A |
| Resistance Level | $0.56 | $0.69 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.81 | 1.73 |
Price Performance
Historical ComparisonAbout MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.